File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Potential Effects of Nutraceuticals in Retinopathy of Prematurity

TitlePotential Effects of Nutraceuticals in Retinopathy of Prematurity
Authors
Keywordscarotenoid
flavonoid
herbal extracts
inflammation
oil
Issue Date2021
PublisherMDPI AG. The Journal's web site is located at https://www.mdpi.com/journal/life
Citation
Life, 2021, v. 11 n. 2, p. article no. 79 How to Cite?
AbstractRetinopathy of prematurity (ROP), the most common cause of childhood blindness, is a hypoxia-induced eye disease characterized by retinal neovascularization. In the normal retina, a well-organized vascular network provides oxygen and nutrients as energy sources to maintain a normal visual function; however, it is disrupted when pathological angiogenesis is induced in ROP patients. Under hypoxia, inadequate oxygen and energy supply lead to oxidative stress and stimulate neovasculature formation as well as affecting the function of photoreceptors. In order to meet the metabolic needs in the developing retina, protection against abnormal vascular formation is one way to manage ROP. Although current treatments provide beneficial effects in reducing the severity of ROP, these invasive therapies may also induce life-long consequences such as systemic structural and functional complications as well as neurodevelopment disruption in the developing infants. Nutritional supplements for the newborns are a novel concept for restoring energy supply by protecting the retinal vasculature and may lead to better ROP management. Nutraceuticals are provided in a non-invasive manner without the developmental side effects associated with current treatments. These nutraceuticals have been investigated through various in vitro and in vivo methods and are indicated to protect retinal vasculature. Here, we reviewed and discussed how the use of these nutraceuticals may be beneficial in ROP prevention and management.
Persistent Identifierhttp://hdl.handle.net/10722/295888
ISSN
2023 Impact Factor: 3.2
2023 SCImago Journal Rankings: 0.713
PubMed Central ID
ISI Accession Number ID
Grants

 

DC FieldValueLanguage
dc.contributor.authorTSANG, JKW-
dc.contributor.authorWolf, SA-
dc.contributor.authorPompoes, IM-
dc.contributor.authorJoussen, AM-
dc.contributor.authorLam, WC-
dc.contributor.authorYang, D-
dc.contributor.authorLo, ACY-
dc.date.accessioned2021-02-08T08:15:27Z-
dc.date.available2021-02-08T08:15:27Z-
dc.date.issued2021-
dc.identifier.citationLife, 2021, v. 11 n. 2, p. article no. 79-
dc.identifier.issn2075-1729-
dc.identifier.urihttp://hdl.handle.net/10722/295888-
dc.description.abstractRetinopathy of prematurity (ROP), the most common cause of childhood blindness, is a hypoxia-induced eye disease characterized by retinal neovascularization. In the normal retina, a well-organized vascular network provides oxygen and nutrients as energy sources to maintain a normal visual function; however, it is disrupted when pathological angiogenesis is induced in ROP patients. Under hypoxia, inadequate oxygen and energy supply lead to oxidative stress and stimulate neovasculature formation as well as affecting the function of photoreceptors. In order to meet the metabolic needs in the developing retina, protection against abnormal vascular formation is one way to manage ROP. Although current treatments provide beneficial effects in reducing the severity of ROP, these invasive therapies may also induce life-long consequences such as systemic structural and functional complications as well as neurodevelopment disruption in the developing infants. Nutritional supplements for the newborns are a novel concept for restoring energy supply by protecting the retinal vasculature and may lead to better ROP management. Nutraceuticals are provided in a non-invasive manner without the developmental side effects associated with current treatments. These nutraceuticals have been investigated through various in vitro and in vivo methods and are indicated to protect retinal vasculature. Here, we reviewed and discussed how the use of these nutraceuticals may be beneficial in ROP prevention and management.-
dc.languageeng-
dc.publisherMDPI AG. The Journal's web site is located at https://www.mdpi.com/journal/life-
dc.relation.ispartofLife-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectcarotenoid-
dc.subjectflavonoid-
dc.subjectherbal extracts-
dc.subjectinflammation-
dc.subjectoil-
dc.titlePotential Effects of Nutraceuticals in Retinopathy of Prematurity-
dc.typeArticle-
dc.identifier.emailLam, WC: waichlam@hku.hk-
dc.identifier.emailLo, ACY: amylo@hku.hk-
dc.identifier.authorityLam, WC=rp02162-
dc.identifier.authorityLo, ACY=rp00425-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/life11020079-
dc.identifier.pmid33499180-
dc.identifier.pmcidPMC7912639-
dc.identifier.scopuseid_2-s2.0-85099916473-
dc.identifier.hkuros321093-
dc.identifier.volume11-
dc.identifier.issue2-
dc.identifier.spagearticle no. 79-
dc.identifier.epagearticle no. 79-
dc.identifier.isiWOS:000622748100001-
dc.publisher.placeSwitzerland-
dc.relation.projectVascular pathophysiology and neuronal dysfunction in gestational diabetes-associated retinopathy of prematurity-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats